Logo

AVTR

Avantor, Inc.

AVTR

Avantor, Inc. • NYSE
$11.73 ▼ -0.09% (-0.01)
Market Cap $8.00 B
52w High $23.32
52w Low $10.82
Dividend Yield 0%
P/E -90.23
Volume 2.82M
Outstanding Shares 681.81M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.624B ▼ $1.175B ▲ $-711.8M ▼ -43.835% ▼ $-1.04 ▼ $-540.8M ▼
Q2-2025 $1.683B ▲ $425.3M ▲ $64.7M ▲ 3.843% ▼ $0.095 ▲ $227.8M ▲
Q1-2025 $1.581B ▼ $387.5M ▲ $64.5M ▼ 4.079% ▼ $0.095 ▼ $227.6M ▼
Q4-2024 $1.687B ▼ $-75.2M ▼ $500.4M ▲ 29.669% ▲ $0.74 ▲ $730M ▲
Q3-2024 $1.714B $439.8M $57.8M 3.371% $0.085 $225.6M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $251.9M ▼ $11.676B ▼ $6.106B ▼ $5.57B ▼
Q2-2025 $449.4M ▲ $12.777B ▲ $6.491B ▲ $6.286B ▲
Q1-2025 $315.7M ▲ $12.326B ▲ $6.228B ▲ $6.098B ▲
Q4-2024 $261.9M ▼ $12.114B ▼ $6.158B ▼ $5.957B ▲
Q3-2024 $285.3M $12.841B $7.287B $5.553B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $7.7M ▼ $154.4M ▲ $-28.6M ▲ $-6.9M ▲ $133.3M ▲ $124.8M ▲
Q1-2025 $60.4M ▼ $109.3M ▼ $-28.9M ▼ $-33.6M ▲ $53.8M ▲ $81.3M ▼
Q4-2024 $500.4M ▲ $173.3M ▼ $558.5M ▲ $-755.3M ▼ $-45.6M ▼ $145.8M ▼
Q3-2024 $57.8M ▼ $244.8M ▼ $-40.5M ▲ $-198.6M ▼ $13.6M ▼ $204M ▼
Q2-2024 $92.9M $281.1M $-44.9M $-197.1M $37.5M $235.3M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Proprietary Materials And Consumables
Proprietary Materials And Consumables
 $900.00M ▲$830.00M ▼$890.00M ▲$860.00M ▼
Third Party Materials And Consumables
Third Party Materials And Consumables
 $790.00M ▲$750.00M ▼$790.00M ▲$770.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Avantor’s sales peaked a couple of years ago and have eased slightly since, suggesting the business is moving from a rapid growth phase into a more mature, steady state. Profitability dipped noticeably in the middle of the period but has since recovered, with recent operating and net income back to levels that look healthy relative to history. This rebound hints that cost actions and mix improvements are helping offset softer top-line trends. Overall, earnings quality appears solid, but future upside likely depends more on margin management and mix than on fast revenue growth.

Balance Sheet

Balance Sheet The balance sheet shows a company that was fairly heavily indebted but has been steadily working that leverage down. Total debt has declined from its prior peak, while shareholders’ equity has built up, which improves the cushion supporting the business. Cash on hand is relatively modest, so Avantor relies on its ongoing cash generation and credit access rather than a large cash war chest. The direction of travel is positive—less debt and more equity—but the company is still meaningfully leveraged, keeping interest costs and refinancing risk as factors to watch.

Cash Flow

Cash Flow Cash flow is a key strength: Avantor has produced consistently solid cash from operations across all five years, even when reported profits temporarily weakened. Investment in capital spending remains disciplined, so a large share of operating cash turns into free cash flow. That free cash flow gives management flexibility to reduce debt, fund selective investments, and absorb periods of softer demand. The profile here is of a dependable cash generator rather than a cash-hungry growth story.

Competitive Edge

Competitive Edge Avantor occupies a strong niche in life sciences and advanced technologies, combining manufacturing of high‑purity materials with a broad distribution platform. Its products and services are deeply embedded in customers’ lab and biomanufacturing workflows, which raises switching costs and supports recurring revenue. A vast catalog, global reach, strict quality systems, and regulatory know‑how all reinforce its position, though it still competes against very large, well‑resourced rivals. Cyclicality in biopharma and research funding can affect demand, but the underlying franchise appears durable and hard to replicate quickly.

Innovation and R&D

Innovation and R&D Innovation is built around close collaboration with customers, using a network of innovation centers to co‑develop customized materials, single‑use solutions, and workflow optimizations. Avantor’s strength in ultra‑high‑purity chemicals, specialized silicones, and differentiated brands gives it room to tailor solutions rather than just sell standard commodities. Digital initiatives—such as advanced e‑commerce, inventory tools, and emerging “smart consumables”—aim to lock Avantor more tightly into customers’ day‑to‑day operations. The main risk is execution: the company must keep pace with rapid changes in bioprocessing, cell and gene therapy, and digital lab infrastructure to maintain its edge.

Summary

Avantor looks like a solid, cash‑generative life sciences enabler that is transitioning from a high‑growth, post‑acquisition and pandemic-boosted phase into a more normalized environment. Recent years show modest revenue softness but improving margins and earnings, supported by methodical debt reduction and stable free cash flow. Its vertically integrated model, sticky customer relationships, and regulatory expertise create a meaningful moat in a demanding, regulated industry. Key watch points include reigniting organic growth in bioprocessing and lab markets, successfully executing its new operating model and cost programs, and continuing to bring innovative, digitally enabled solutions to market while carefully managing its still‑significant leverage.

NEWS

November 29, 2025 · 5:35 PM UTC

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

Read more

November 29, 2025 · 8:44 AM UTC

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor

Read more

November 28, 2025 · 5:30 PM UTC

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

Read more

November 28, 2025 · 12:46 PM UTC

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

Read more

November 28, 2025 · 11:20 AM UTC

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor

Read more